文献速递乳腺癌支持与姑息治疗

机器学习和患者报告结局用于转移性乳腺癌疾病进展的纵向监测:一项多中心回顾性分析

Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis.
PubMed 文献 · Eur J Cancer · 2023-04-29

研究从两家机构纳入179例转移性乳腺癌患者,通过在线平台在6个月内重复采集EQ-VAS评分,用正则化回归算法(10折交叉验证)基于第1-6周评分变化预测第12周疾病进展,并在另一机构数据上验证。验证集63例中,智能EQ-VAS高风险组中位无进展生存期7周 vs 低风险组10周(log-rank P<0.038),校正后风险比2.69(95%CI 1.17-6.18,P=0.02)。作者认为机器学习可分析纵向健康相关生活质量数据,比标准随访方法更早识别疾病进展患者。

要点

  • 179例患者中98例(54.7%)在中位随访14周后出现疾病进展。
  • 验证集63例中,智能EQ-VAS高风险组中位PFS 7周 vs 低风险组10周(log-rank P<0.038)。
  • 智能EQ-VAS与PFS独立相关,校正后风险比2.69(95%CI 1.17-6.18,P=0.02)。

核心结论

  • 机器学习算法可分析纵向健康相关生活质量数据的变化,比标准随访方法更早识别疾病进展患者。
  • 智能EQ-VAS评分被识别为独立预后因素。
  • 作者指出未来研究可验证这些结果以用于远程监测患者。

研究设计与样本

  • 多中心回顾性分析,从两家机构招募患者,通过在线平台在6个月期间施测EuroQoL视觉模拟量表(EQ-VAS)。
  • 使用一家机构数据训练正则化回归算法(10折交叉验证),基于EQ-VAS评分变化判断疾病进展高风险或低风险,并在另一机构数据上验证性能。
  • 终点为无进展生存期(PFS),采用Kaplan-Meier分析和校正临床危险因素的Cox回归分析。
  • 共纳入179例患者,验证集63例。

主要发现

  • 179例患者中98例(54.7%)在中位随访14周后出现疾病进展。
  • 使用第1-6周采集的EQ-VAS评分预测第12周疾病进展,验证集(n=63)中智能EQ-VAS高风险组中位PFS 7周 vs 低风险组10周(log-rank P<0.038)。
  • 智能EQ-VAS与PFS关联最强,校正后风险比2.69(95%CI 1.17-6.18,P=0.02)。

临床怎么用

  • 作者认为机器学习算法可分析纵向健康相关生活质量数据的变化,比标准随访方法更早识别疾病进展患者。
  • 作者指出未来研究可验证这些结果以用于远程监测患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Assessments of health-related quality of life (HRQoL) play an important role in transition to palliative care for women with metastatic breast cancer. We developed machine learning (ML) algorithms to analyse longitudinal HRQoL data and identify patients who may benefit from palliative care due to disease progression. METHODS: We recruited patients from two institutions and administered the EuroQoL Visual Analog Scale (EQ-VAS) via an online platform over a 6-month period. We trained a regularised regression algorithm using 10-fold cross-validation to determine if a patient was at high or low risk of disease progression based on changes in the EQ-VAS scores using data of one institution and validated the performance on data of the other institution. Progression-free survival (PFS) was the end-point. We conducted Kaplan-Meier and Cox regression analysis adjusted for clinical risk factors. RESULTS: Of 179 patients, 98 (54.7%) had progressive disease after a median follow-up of 14weeks. Using EQ-VAS scores collected at weeks 1-6 to predict disease progression at week 12, in the validation set (n = 63), PFS was significantly lower in the intelligent EQ-VAS high-risk versus low-risk group: median PFS 7 versus 10weeks, log-rank P < 0.038). Intelligent EQ-VAS had the strongest association with PFS (adjusted hazard ratio 2.69, 95% confidence interval 1.17-6.18, P = 0.02). CONCLUSION: ML algorithms can analyse changes in longitudinal HRQoL data to identify patients with disease progression earlier than standard follow-up methods. Intelligent EQ-VAS scores were identified as independent prognostic factor. Future studies may validate these results to remotely monitor patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Deutsch TM, Pfob A, Brusniak K, et al. Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis. Eur J Cancer. 2023. PMID: 37229835. doi:10.1016/j.ejca.2023.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。